Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth
Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of the Company’s pipeline of non-opioid pain treatment programs
Covered in this story
Call it yourself
No calls on $LTGO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Latigo Biotherapeutics, Inc. →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.